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INTRODUCTION
Large skeletal defects require bone grafts for
regeneration. The availability of autografts may be limi-
ted and associated with significant donor site mor-
bidity [19, 45, 46]. Allografts bear the risk of immu-
nological rejection and disease transmission [22];
therefore, bone graft substitutes (BGS) are widely
used in clinical practice. They include hydroxyapa-
tite and beta-tricalcium phosphate ceramics [11, 40],
demineralised bone composites [5, 32], and poly-
mers consisting of polyglycolic and polylactic acids
[24]. Bone graft substitutes should maintain spatial
integrity, provide biomechanical stability, allow for
cell attachment, vascular ingrowth, and bone de-
position, and should be degradable, ultimately lead-
ing to complete replacement by bone [6].
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Bone graft substitutes (BGS) are widely used in clinical practice. For stem cell-
based approaches to bone tissue engineering BGS need to show sufficient
biocompatibility in the in vitro setting. This study was designed to demonstrate
the influence of six different BGS on the proliferation and metabolic activity of
porcine mesenchymal multilineage stem cells (pMSC) in vitro.
Bone-marrow derived pMSC were cultivated for 24 hours with the eluates of
six different BGS. The eluates were generated by incubating the BGS three
times in succession for 24 hours with a culture medium and collecting the
supernatants. pMSC vitality and proliferation in the presence of eluates from
the first, second, and third incubation were assessed by WST-test quantifica-
tion of metabolically active cells.
Culture of pMSC with eluates in all cases resulted in decreased cell numbers in
an eluate concentration-dependent manner. At least a 65% loss of cells com-
pared to controls (culture medium without eluates) could be observed in the
presence of undiluted eluates. The negative influence of eluates varied signifi-
cantly among BGS. In all cases, second and third eluates were less potent in
their negative effects on cellular vitality/proliferation.
In conclusion, the BGS examined here should be submitted to thorough prein-
cubation before in vitro use for cell-based constructs to maximize cell viability
for the tissue engineering of bone. (Folia Morphol 2011; 70, 3: 154–160)
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The effectiveness of BGS may be enhanced by
combining appropriate scaffolds with osteogenic
cells [34].
Since the discovery and isolation of bone-form-
ing cells from adult bone marrow by Friedenstein
and colleagues [8, 9, 26], who referred to them as
colony forming unit fibroblasts (CFU-F) or bone
marrow stromal stem cells (BMSC), research has
focussed on cultivating and characterising these
stem cells in vitro [4]. Their multilineage potential
has been demonstrated in humans [28] and other
species [3, 30].
Multilineage stem cells have proven to be an ex-
cellent source of osteogenic cells. When combined
with BGS these stem cells may enhance bone rege-
neration in vivo [4, 10, 16, 35]. For tissue engineering
purposes, i.e. the in vitro cultivation of cell-seeded
constructs, scaffold materials should support mul-
tilineage stem cells viability to minimise the amount
of donor cells needed while providing high num-
bers of functional osteogenic cells.
Most studies on the biocompatibility of BGS
were designed as seeding experiments [23, 37]
and have used continuous cells lines [25, 38, 41],
osteoblasts [1, 18], fibroblasts [15] or other non-
osteogenic cells [43]. In addition, most studies
deal with the testing of single BGS rendering di-
rect comparison between different BGS impossi-
ble. Finally, information on the early effects of BGS
on cell metabolism is scarce.
This study was designed to demonstrate and com-
pare the early effects of six different BGS on the pro-
liferation and metabolic activity of porcine mesen-
chymal multilineage stem cells (pMSC) in vitro.
MATERIAL AND METHODS
This study was approved by the Minister of Na-
ture, Environment, and Forestry of Schleswig-Hol-
stein and was in accordance with the local ethics
committee (V 742-72241.121-1415-2/04).
Bone graft substitutes
Six different types of sterile BGS of diverse
chemical and morphological type were purchased
and stored at room temperature (Table 1). They
were biologically derived or synthetic granular
materials typically found in current clinical prac-
tice: BioOss® (Geistlich, Wolhusen, Switzerland)
[12, 13, 48], Straumann Bone Ceramic® (Strau-
mann AG, Freiburg, Germany), Cerasorb® (Curasan
AG, Kleinostheim, Germany) [27], NanoBone® (Ar-
toss GmbH, Rostock, Germany), NovaBone-OM®
(NovaBone Products, Alachua, Fl, USA), and Pep-
gen P15® (Friadent GmbH, Mannheim, Germany)
[25, 29, 39].
Generation of BGS eluates
Material properties of BGS, such as particle size,
surface morphology, electric charge, porosity, and
pore size, may significantly influence cell adherence
[7, 17, 21], proliferation, and phenotype [47], mak-
ing direct comparison between the various BGS dif-
ficult. In contrast to common seeding experiments,
BGS eluates were used to reduce the complexity of
in vitro culture conditions and render comparison
among the various BGS possible. All experiments
were conducted in triplicate.
BGS eluates were generated by incubating 0.1 mL
of each BGS three times in succession for 24 h
with 1 mL of culture medium (CM) at 37°C and col-
lecting the supernatants. This time period of 72 h
was chosen to evaluate the early effects of soluble
factors released from the BGS as well as to examine
time dependent effects. The resulting eluates of the
first, second, and third incubation were stored at
4°C until further use, to cultivate pMSC (see below).
Table 1. Characteristics of bone graft substitutes with good biocompatibility in the in vivo setting
Brand name Material Granule size [mm] Porosity [%] Pore size [µm]
BioOss® Deproteinised bovine bone 1–2
Straumann Synthetic, 60% HA, 40% b-TCP 0.5–1.0 90 100–500
Bone Ceramic®
Cerasorb® Synthetic, > 99% b-TCP sintered at > 1000°C 0.5–1.0 30 ± 5 0.1–50
NanoBone® Synthetic, 76% HA, 24% SiO2 manufactured at 700°C 0.6 > 80 0.01–0.02
NovaBone-OM® Synthetic, Si, Na, Ca, P, O 0.09–1.0
Pepgen P15® Bovine HA coated with peptide (= active domain of collagen I) 0.25–0.42
HA — hydroxyapatite; b-TCP — b-tricalcium phosphate
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Cell source and cell culture
Multilineage stem cells were harvested from the ili-
ac bone marrow of an adult (23 months old) Göttin-
gen minipig (Ellegaard Göttingen Minipigs A/S, Dal-
mose, Denmark), as previously described [20]. Briefly,
under general anaesthesia with ketamine and xylazine
and aseptic conditions, approximately 1.5 mL of spon-
gious bone were harvested, dissected into small frag-
ments of 0.1–0.5 cm, and pretreated with 0.1% colla-
genase (Nordmark, Uetersen, Germany) for 2 h at 37°C.
After thoroughly rinsing with PBS (pH = 7.4) to remove
collagenase solution, the cells were stained with 4%
trypan blue (Gibco, Paisly, Scottland, UK), counted in
a haemocytometer, and plated at a density of 5,000 cells/
/cm2 in T75 tissue culture flasks (passage 0). The CM
consisted of Dulbecco’s modified Eagle medium
(DMEM) supplemented with 105 IU/L penicillin, 100 mg/L
streptomycin (all Biochrom AG, Berlin, Germany),
1 mM L-ascorbic acid (Sigma, Deisenhofen, Germany), and
10% FCS. Cells were cultivated under standard condi-
tions at 37°C in a humidified atmosphere of 95% air
and 5% CO2. The medium was changed first after 24 h
to remove non-adherent cells, and twice per week there-
after. At 70–80% confluence (on day 14), cells were
detached under microscopic control after washing with
D-PBS (Gibco, Paisly, Scottland, UK) for 2 min followed
by incubation with Accutase (PAA, Cölbe, Germany) for
15 min at 37°C. Detached cells were suspended in CM,
centrifuged for 5 min at 1,200 rpm, re-suspended in
CM, stained with trypan blue, counted as above, re-
plated at a density of 2,500 cells/cm2 (passage 1), and
cultivated until subconfluent (70–80%) again. Subcul-
tivation was further continued to passage 3 as de-
scribed. This allowed for standardisation because the
same cell line was used for all experiments.
Characterisation of pMSC
Bone marrow-derived porcine cells were characte-
rised for their multilineage potential by cultivation with
osteogenic and adipogenic induction media. Briefly the
cells were seeded in 6-well plates at a density of 5,000
cells/cm2 and cultivated with CM for 7 days until sub-
confluent. For osteogenic or adipogenic induction, cul-
tivation was continued with either osteogenic or adi-
pogenic induction medium for 14 days. Osteogenic
induction medium consisted of CM supplemented with
100 nM dexamethasone, 10 mM beta-glycerol phos-
phate, 230 mg/L CaCl2, and 52 mg/L L-ascorbic acid (all
Sigma, Deisenhofen, Germany). Adipogenic induction
medium (Adipogenic Differentiation Media BulletKits,
Cambrex Bio Science, Walkersville, MD, USA) was used
according to the manufacturer’s instructions. Cells cul-
tivated for 14 days with CM but without induction fac-
tors served as controls. All media were changed twice
per week. After 14 days the cells were rinsed with PBS,
fixed with 4% paraformaldehyde for 10 min, and rinsed
again with PBS. Osteogenic or adipogenic differentia-
tion was evaluated after staining with Alizarin Red S or
Oil Red O, respectively, by microscopic examination of
the presence of extracellular calcium complexes or in-
tracellular fat vesicles, respectively.
Biocompatibility testing
Expanded subconfluent pMSC of passage 3 were
seeded in duplicate on 96-well plates at a density of
5,000 cells per well (samples) in 100 µL of CM and
allowed to adhere to the plate. A duplicate stan-
dard row of 20,000, 10,000, 5,000, 2,500, 1,250,
625, 312, and 156 cells per well in 100 µL of CM
served to establish a standard curve (standard) on
each plate. Wells with 100 µL CM but without cells
served as negative controls (blanks). Identical ho-
mogenous distribution of cells throughout the sam-
ple wells was confirmed by microscopic examina-
tion after 24 h of cultivation.
Adherent cells were then cultivated with previously
generated first, second, and third incubation eluates
of the six different BGS (see above). To study concen-
tration dependent effects, eluates were used undi-
luted (100%) or diluted with CM at a ratio of 1:1
(50%), 1:3 (25%), or 1:7 (12.5%). Wells cultivated with
CM only (i.e. 0% eluates) served as controls.
After 24 h of eluate culture pMSC viability and
proliferation were assessed by quantification of
metabolically active cells using the WST-1 test (Roche
Diagnostics GmbH, Mannheim, Germany) [2]. Ac-
cording to the manufacturer’s instruction the medi-
um was replaced by a 10% WST-1 solution. After
45 min of incubation at 37°C, WST-1 cleavage and
formazan formation by metabolically active cells was
measured photometrically at 450 nm with an ELISA
96-well plate reader (SPECTRAmax® PLUS, Molecu-
lar Devices, Sunnyvale, CA, USA). Six measurements
per BGS and type of eluate were recorded.
Statistical evaluation
Statistical analysis consisted of a two-factorial
analysis of variance for repeated measures of extinc-
tion values. The significance level was set at p < 0.05.
RESULTS
Porcine bone marrow-derived cells showed mul-
tilineage potential after 14 days of osteogenic or
adipogenic induction as demonstrated by the pres-
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ence of extracellular calcium complexes or intracellu-
lar lipid vesicles, respectively. Cells cultured without
inductions factors (controls) did not form calcium
complexes or intracellular lipid vesicles (Figs. 1, 2).
Culture of pMSC with BGS eluates resulted in sig-
nificantly decreased cell numbers in all cases. At least
a 65% loss of cells compared to controls (CM with-
out eluates) was observed in the presence of undi-
luted eluates (Fig. 3A). The differences between un-
diluted eluates and 50%-eluates were significant
(p < 0.001), as were the differences between 50%,
25%, and 12.5%-eluates (p < 0.05).
The negative influence of eluates from the vario-
us BGS differed. For first incubation eluates, BioOss®
decreased vitality most and NovaBone-OM® least. The
others ranged in between in the following order:
BioOss® < NanoBone® < Straumann Bone Ceramic®
< Cerasorb® < Pepgen P15® < NovaBone-OM® (p < 0.05).
For second and third incubation eluates, the diffe-
rences between BGS were similar but not statistically
significant. Independent of the type of BGS, dilution
of eluates resulted in an increase of metabolically
active cells (p < 0.001). In all cases, second and third
eluates were less potent in their effect on cellular
vitality/proliferation (p < 0.01) (Fig. 3B).
DISCUSSION
In all cases BGS eluates had a negative effect on cell
survival and proliferative activity, resulting in significantly
reduced cell numbers when compared to controls. At
most, only one third of adherent cells survived when
cultivated with BGS eluates for 24 h. This may be ex-
plained by a toxic effect eluted from the BGS, such as
changes in pH-value seen with synthetic hydroxyapa-
tites [31]. Jäger et al. [14] reported extensive H+ re-
lease by BGS incubated in DMEM (pH 7.4–7.6) for 24 h.
They found significant differences in H+ concentrations
between the tested materials. While Cerasorb® led to
an increase in pH to 8.09, non-demineralized bovine
bone (Lubboc™, Ost, Developpement, France) and dem-
ineralized human bone caused a decrease in pH to 7.3
and 6.66, respectively. Cell survival after 4 days of elu-
ate culture was higher for Cerasorb® than for non-demi-
neralized bovine bone or decalcified human bone,
which is consistent with the findings of this study
Kauschke et al. [15] used the Alamar Blue assay
to measure metabolic activity of mouse and human
fibroblasts during 28 days and 24 days of culture
with Straumann Bone Ceramic® and NanoBone®.
They demonstrated equal cytotoxicity of these two
BGS, which is in accordance with the neighbouring
Figure 1. Phase contrast microscopy of pMSC cultivated for 14 days with (A) or without (B) osteogenic supplements and stained with
Alizarin Red S. Osteogenic potential of induced cells is indicated by the presence of extracellular calcium complexes; bar = 200 µm.
Figure 2. Phase contrast microscopy of pMSC cultivated for 14 days with (A) or without (B) adipogenic supplements and stained with Oil
Red O. Adipogenic potential of induced cells is indicated by the presence of intracellular fat vesicles; bar = 200 µm.
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ranking positions shown here. Viability on day 2 of
culture was about 50% and 60%, respectively, of
control cultures (cells without BGS) for the two ma-
terials. The authors attribute the reduction of meta-
bolic activity to BGS surface characteristics. In this
study, in which surface characteristics were unim-
portant, cell viability after 24 hours of culture with
BGS eluates was reduced to about 15% of controls,
and a concentration dependent effect could be ob-
served for all materials including NanoBone®.
Trasatti et al. [39] measured higher concentrations
of TGF-b1 in supernatants of rat osteoblasts when
cultured with Pepgen P15® compared to BioOss®.
Nguyen et al. [25] reported twofold higher cell via-
bility by MTT-assay of human osteosarcoma cells
4 days after seeding onto anorganic bovine bone ma-
trix coated with the P15-peptide compared to P15-
-peptide-free controls. Kübler et al. [18] used the
WST-1 test to assess the viability of human osteoblasts
after 6 and 9 days of culture with five different BGS,
including BioOss® and Pepgen P15®. While cell proli-
feration and viability of Pepgen P15® cultures were
equal or higher than control cultures without BGS,
values for BioOss® cultures were lowest of all BGS
tested, amounting to about one third of control va-
lues. Wiedmann et al. [44] measured the viability of
human osteoblast-like cells cultivated for one week
on 16 different biomaterials, including collagen, tri-
calcium phosphates, hyaluronic acid, silicone, and
anorganic bovine bone (BioOss®), using the EZ4U as-
say. While none of the materials reached control va-
lues, cells cultured with BioOss® showed the lowest
metabolic activity (~20%) of controls. Turhani et al.
[42] measured total DNA content from human os-
teoblasts after 6 days of culture on Pepgen P15® and
BioOss® using the PicoGreen assay. While values in
Pepgen P15® cultures were not significantly lower
than controls, DNA content in BioOss® cultures was
less than 10% of controls. All these findings are con-
sistent with the results of this study, in which eluates
of Pepgen P15® led to a higher number of metaboli-
cally active cells than eluates of BioOss®.
Apart from H+ release, substances needed dur-
ing manufacturing (e.g. glycerol for storage, acid for
decalcification) or the BGS itself (residual mineral) may
be responsible for cell death in in vitro assays.
Due to limited resources of BGS and pMSC we were
unable to repeat the experiments and analyse eluate
composition or pH. Theoretically it is conceivable that,
apart from toxic substances being released from BGS
into the eluate during incubation, factors within the
medium, which enhance cell viability and proliferation,
Figure 3. Results of WST-1 test after cultivation of pMSC with eluates of six different bone graft substitutes (BGS); A. At all concentra-
tions, cultivation of pMSC with first incubation eluates (24 h) resulted in significantly reduced cell numbers of max. 35% of controls (cul-
ture medium without BGS); differences in cell numbers among BGS cultivated with undiluted first incubation eluates were significant;
B. Second and third BGS eluates resulted in a significant increase in cell numbers; *p < 0.05, **p < 0.01, ***p < 0.001.
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e.g. growth factors, could be removed from the elu-
ate by binding to the BGS during incubation. During
second and third incubation, with binding sites being
increasingly occupied, their relative concentration in
the eluate would increase, which could account for
higher cell numbers in second and third incubation
eluates. Also, by diluting eluates with CM, the con-
centration of “favourable factors” would increase
through the addition of CM. It has been shown that
binding proteins to BGS surfaces enhances adherence
and proliferation [33, 36]. To test this hypothesis, seed-
ing experiments with the BGS and pMSC of this study
were conducted [47]. Cell adherence and proliferation
significantly depended on the type of BGS, and cell
densities at different time points paralleled the results
of the present study. Therefore, the above hypothesis
of a “steal effect” can be rejected.
While the BGS tested here have shown good bio-
compatibility in clinical trials, in vitro conditions differ
from the in vivo setting. Thus, the results of this study
cannot be transferred to the in vivo situation. Since
the concept of tissue engineering involves the combi-
nation of biomaterials, cells, and growth factors in vit-
ro, i.e. the cultivation of seeded constructs for in vivo
implantation, there is a need to study the in vitro ef-
fects of BGS for tissue engineering applications.
CONCLUSIONS
In conclusion, the eluates of the BGS tested here
had a negative effect on cell survival of pMSC cultured
in vitro. The negative influence exerted by second and
third eluates was significantly lower. Thus, BGS should
be submitted to (repeated) preincubation washes pri-
or to cell seeding, in order to ascertain cell viability
and a solid proliferative response of mesenchymal
multilineage stem cells in vitro. Future studies should
be directed towards optimising cell viability in vitro
for the applications of engineered constructs in vivo.
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